Evidence map›Paper›PMID 33204688›Full record

ArticleBioMed research international2020

Hemangiopericytoma: Incidence, Treatment, and Prognosis Analysis Based on SEER Database.

Kewei Wang, Fei Mei, Sisi Wu, Zui Tan

Abstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Haemangiopericytoma and solitary fibrous tumour of the parotid gland: a scoping review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kewei WangDepartment of Thoracic and Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0001-6576-6419
Fei MeiDepartment of Vascular Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, China.
Sisi WuCenter of Clinical Reproductive Medicine, The First College of Clinical Medical Science, China Three Gorges University, Yichang, China.
Zui TanDepartment of Thoracic and Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0002-3583-6989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHemangiopericytomas are rare tumors derived from pericytes surrounding the blood vessels. The clinicopathological characteristics and prognosis of hemangiopericytoma patients remain mostly unknown. In this retrospective cohort study, we assessed the clinicopathological characteristics of hemangiopericytoma patients, as well as the clinical usefulness of different treatment modalities.

resultsData from 1474 patients were analyzed in our study cohort (hemangiopericytoma:

conclusionsOur findings suggested that hemangiopericytoma had a similar prognosis with hemangioendothelioma. Surgery was the only effective treatment that provided survival benefits in hemangiopericytoma patients, while the clinical usefulness of adjuvant chemotherapy or radiotherapy was limited.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHemangioendotheliomaHemangiopericytomaHumansIncidenceInfantMaleMiddle AgedPrognosisRetrospective Studies

Identifiers

PMID33204688
PMCPMC7655240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.